NDAORALTABLETPriority Review
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
JAYPIRCA (pirtobrutinib) by Eli Lilly and Company is bruton's tyrosine kinase inhibitors [moa]. First approved in 2023.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JAYPIRCA (pirtobrutinib) is an oral Bruton's Tyrosine Kinase (BTK) inhibitor approved by the FDA on January 27, 2023. It is a small-molecule kinase inhibitor designed to treat B-cell malignancies by blocking BTK signaling. The drug represents a non-covalent BTK inhibitor option in a competitive oncology space.
$49MPart D
Peak15.0 years to LOEEarly-stage peak lifecycle with modest Part D penetration signals a maturing product that requires sustained market access and managed care strategy to drive adoption.
Mechanism of Action
Bruton's Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
Started Oct 2026
280 enrolled
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Started Aug 2026
620 enrolled
B-cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
Started Jun 2026
25 enrolled
Waldenstrom Macroglobulinemia
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Started Apr 2026
306 enrolled
CLL / SLLCLL (Chronic Lymphocytic Leukemia)CLL, Refractory+5 more
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Started Mar 2026
150 enrolled
Chronic Lymphocytic LeukemiaLymphoma, Small Lymphocytic
Worked on JAYPIRCA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.